Genetic Technology Alert. Enhancement of T-Cell Therapy Using Oncolytic Viruses; T-Cell Therapy Utilized in Restricting Brain Tumors; Novel Autologous Cell Therapy Using Chimeric Antigen Receptors

USD 250

* Required Fields

USD 250

PAY BY INVOICE

Be the first to review this product

This issue profiles enhancement of T-cell therapy using oncolytic viruses, utilizing T-cell therapy for restricting brain tumors, and a novel autologous cell therapy that uses chimeric antigen receptors.

Table of Contents

Genetic Technology Alert. Enhancement of T-Cell Therapy Using Oncolytic Viruses; T-Cell Therapy Utilized in Restricting Brain Tumors; Novel Autologous Cell Therapy Using Chimeric Antigen ReceptorsIn This Issue1. ENHANCEMENT OF T-CELL THERAPY USING ONCOLYTIC VIRUSES2. T-CELL THERAPY UTILIZED IN RESTRICTING BRAIN TUMORS3. NOVEL AUTOLOGOUS CELL THERAPY USING CHIMERIC ANTIGEN RECEPTORS4. RECENT PATENTS IN T-CELL THERAPY




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 31-Oct-17

Region : Global

Release Date : 19-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Related Subscription

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.